Asahi Kasei Group’s medical devices manufacturer ZOLL Medical has signed a strategic multi-year research and development (R&D) collaboration agreement with technology and soft electronics firm Myant for ZOLL LifeVest wearable defibrillator.
Under the terms of the agreement, the firms will jointly develop technologies to be utilised in future generations of the wearable defibrillator.
The LifeVest device is developed for patients who are at risk of sudden cardiac death (SCD) to provide protection during their changing condition and when permanent SCD risk has not been determined.
It is designed to monitor heart rate and upon detection of a life-threatening heart rhythm, the device delivers a treatment shock to restore normal rhythm.
The firms intend to combine the benefits of advanced materials science, machines, yarn with nanotechnology and manufacturing.
ZOLL LifeVest president Jason Whiting said: “This collaboration with Myant aligns with ZOLL’s longstanding commitment to research and development with the goal of improving patient outcomes.
“We are excited to combine efforts with Myant and leverage their strong R&D capabilities, advanced manufacturing, and broad research capabilities from its Centres for Excellence in Canada and the US.”
The LifeVest wearable defibrillator is indicated for a variety of patient conditions such as myocardial infarction, coronary revascularisation, cardiomyopathy, or congestive heart failure.
Established in 2010, Myant creates a computing textile platform to sense, record, analyse and respond, while it ambiently interfaces with humans and artificial intelligence (AI) through textiles.